A Study of LY3462817 in Participants With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

January 10, 2022

Study Completion Date

June 29, 2022

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Placebo

Given IV

DRUG

LY3462817

Given IV

Trial Locations (26)

909

Latin Clinical Trial Center, San Juan

1027

Revita Clinic, Budapest

Budai Irgalmasrendi Korhaz, Budapest

1033

Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft., Budapest

3529

CRU Hungary Kft., Miskolc

8200

Vital Medical Center, Veszprém

16635

Altoona Center For Clinical Research, Duncansville

21100

Centro Medico del Angel, Mexicali

31000

Investigacion y Biomedicina de Chihuahua, Chihuahua City

44690

Centro de Estudios de Investigacion Basica y Clinica, S.C., Guadalajara

68516

Physician Research Collaboration, LLC, Lincoln

73103

Health Research of Oklahoma, Oklahoma City

85037

Arizona Arthritis & Rheumatology Associates, P. C., Phoenix

85210

Arizona Arthritis & Rheumatology Associates, P. C., Mesa

91786

Inland Rheumatology & Osteoporosis Medical Group, Upland

92260

Desert Medical Advances, Palm Desert

97070

Köhler & Milstein Research, Mérida

686 01

Medical Plus, Uherské Hradiště

760 01

PV Medical Services s.r.o., Zlín

03100

RM Pharma Specialists S.A. de C.V., Mexico City

85-168

Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej, Bydgoszcz

67-100

Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa Sól

02-691

Reumatika - Centrum Reumatologii, Warsaw

41-902

Nzoz Bif-Med, Bytom

00725

Centro Reumatologico Caguas, Caguas

EN53DJ

Royal Free Hospital, Barnet

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04634253 - A Study of LY3462817 in Participants With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter